[Drug-resistant B cell chronic lymphocytic leukemia safely treated with rituximab to control leukemic cell increment...

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• B-cell chronic lymphocytic leukemia (B-CLL) is a common lymphoid malignancy.
• Chemotherapy resistance and transformation are significant challenges in B-CLL management.
• Monoclonal B-cell proliferation in bone marrow indicates B-CLL diagnosis.

Observation:

• A 61-year-old male diagnosed with B-CLL in 1993 experienced disease progression.
• Initial treatments with chlorambucil and fludarabine became ineffective.
• The patient developed uncontrollable proliferation of transformed cells and platelet transfusion dependence.

Findings:

• Rituximab therapy (15,500 mg total dose over 32 administrations) was administered to a patient with refractory B-CLL.
• The treatment was well-tolerated, with manageable toxicity.
• The patient achieved transfusion independence for six months.

Implications:

• Rituximab demonstrates a favorable safety profile in treating refractory B-CLL.
• While systemic disease control was limited, rituximab improved hematological parameters.
• Further research into optimizing rituximab for advanced B-CLL is warranted.